Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model?

Abstract

The pharmacokinetics of morphine are well known in pre-term and term neonates, infants, younger and older children, as well as in adults. There are circumstances when a pharmacokinetic study may not be possible in children (especially neonates and infants), and as a result one would like to predict drug clearance in children. Several methods, such as allometric scaling and prediction based on incorporation of physiological parameters, have been suggested. Recently a morphine maturation model has been proposed to predict morphine clearance in the paediatric population. WHAT THIS STUDY ADDSThe current study evaluates the predictive performance of the morphine maturation model for the prediction of morphine clearance in pre-term, term, infants and children up to 5 years of age. The results of the study highlight the shortcomings of the model to predict morphine clearance in children in aforementioned age groups. AIMSRecently, a maturation model that incorporates a sigmoidal Emax type model has been proposed for the estimation of morphine clearance in paediatric patients. The primary objective of this report is to evaluate the predictive performance of the morphine maturation model for the prediction of morphine clearance in children of different ages. The secondary objective of this report is to evaluate the predictive performance of exponent 0.75 on bodyweight in the absence of the sigmoidal part of the morphine maturation model. METHODSIn order to evaluate the predictive performance of the morphine maturation model, the clearance values of morphine for individual children (preterm neonates to 5-year-old children; n = 147) were obtained from the literature. The predicted clearance of morphine in an individual child, obtained from the maturation model as well as from the fixed exponent 0.75 was compared with the observed clearance in that individual child. RESULTSThe morphine maturation model's predictive power in neonates, infants and younger children is poor and the inclusion of the sigmoidal part in the model only helps in reducing the substantial error introduced in the prediction due to the application of exponent 0.75 on bodyweight. Furthermore, the real benefit of the sigmoidal Emax part of the model disappears by 1 year of age. CONCLUSIONSThe morphine maturation model has a poor predictive power of morphine clearance in preterm and term neonates, infants and very young children and may not be of any practical value for the prediction of morphine clearance in this age group.

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping

“…However, the selected %MPE and %MAE acceptance limits were arbitrary. Studies utilizing higher acceptance limits have been reported, but mostly in patients and/or in situations where variability of the evaluated pharmacokinetic parameter is expected to be high [41]. Conservative acceptance limits (e.g., -15% to 15%) were selected due to the anticipated decreased variability of midazolam CL ORAL in healthy adults compared to patients.…”

Prediction of morphine dose in humans

“…While these local models may provide reasonable descriptions of a particular age group, they are of little value from a global perspective if they do not predict to other age groups. Evaluation of global applicability, by extrapolation to a wider range of patients, has been proposed (17) but has not been previously evaluated using an external, independent data set. The use of a global model not only informs about common underlying processes but can also lead to new directions of investigation.…”

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction

“…4 Studies using higher acceptance limits (eg, ,25%) have been used primarily in patient populations or in situations where high pharmacokinetic variability is anticipated. 21 When higher acceptance limits were applied to the currently evaluated studies, the study using data from advanced-stage cancer patients (study 6), revealed %MPE, %MAE, and/or %RMSE still exceeded 25% (Table 3).…”